MediciNova (MNOV) - P/S ratio

P/S ratio as of June 2026 (TTM): 250

According to MediciNova's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.47. At the end of 2025 the company had a P/S ratio of 242.

P/S ratio history for MediciNova from 2006 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	242
2024	N/A	-100%
2023	73.6
2022	N/A	-100%
2021	32.6
2020	N/A
2019	N/A
2018	N/A
2017	N/A
2016	N/A
2015	N/A
2014	N/A	-100%
2013	8.02	-77.45%
2012	35.6
2011	N/A
2010	N/A
2009	N/A
2006	490

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Novartis NVS	5.03	-97.99%	🇨🇭 Switzerland
Eli Lilly LLY	14.0	-94.41%	🇺🇸 USA
Sanofi SNY	1.94	-99.22%	🇫🇷 France
Titan Pharmaceuticals TTNP	N/A	N/A	🇺🇸 USA
Alkermes ALKS	4.57	-98.17%	🇮🇪 Ireland
Teva Pharmaceutical Industries TEVA	2.29	-99.08%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for MediciNova (MNOV)

P/S ratio as of June 2026 (TTM): 250